In February this year, Redsense Medical announced positive results from a multicenter pilot study with the company’s blood leakage alarm that was conducted by a large international dialysis care provider. The study indicated that Redsense was effective in detecting venous blood loss. Redsense was also found to be an uncomplicated and straightforward device to use, without adding any extra burden when performing dialysis treatments.   

Based on these results, the dialysis care provider has now decided to make Redsense available at selected hospitals with special needs. It will be available on an as-needed basis for acute care patients who require dialysis.  

The dialysis provider will oversee this soft rollout of Redsense, which will add to its collection of patient usage data.

“We are excited that this large international dialysis care provider will make our blood leakage alarm available to dialysis patients at selected hospitals. Every new adoption and treatment using Redsense takes us closer to the day when dialysis care providers realize that universal implementation of our device is the only logical solution to protect dialysis patients from catastrophic venous blood loss. In addition to the benefits for the patients, it would be a financially accountable decision, based on available and robust medical and economic data,” says Redsense Medical’s CEO Patrik Byhmer.

For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
Email: patrik.byhmer@redsensemedical.com
Website: www.redsensemedical.com

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company"s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

This information is insider information that Redsense Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on 24 June 2019.